Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CING | US
-0.26
-4.51%
Healthcare
Biotechnology
30/06/2024
13/04/2026
5.50
5.81
5.95
5.36
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
68.1%1 month
156.0%3 months
122.3%6 months
97.5%-
-
4.53
0.11
0.06
-0.36
-
-
-18.05M
16.74M
16.74M
-
-
-
-
-1.36K
0.05
0.95
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.40
Range1M
6.53
Range3M
7.48
Rel. volume
0.85
Price X volume
3.23M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| PLUR | PLUR | Biotechnology | 3.3407 | 18.27M | 0.62% | n/a | 30845.83% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 0.8382 | 17.94M | -12.82% | n/a | 2.92% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.92 | 17.80M | 0.00% | n/a | 0.00% |
| ICU | ICU | Biotechnology | 4.21 | 17.65M | 13.48% | n/a | -45.50% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 1.97 | 17.57M | 0.36% | n/a | 0.00% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.71 | 17.06M | 0.59% | n/a | 3.49% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.63 | 16.17M | 3.14% | n/a | 54.59% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 1.12 | 16.08M | -3.45% | n/a | 11.72% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.576 | 15.58M | 2.78% | n/a | 1.90% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.74 | 15.53M | -0.57% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 122.32 | 72.80 | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 16.74M | 3.66B | Emerging |